By Josh Beckerman 



  Voyager Therapeutics Inc. shares fell 15% to $9.62 after hours as the gene therapy company reported the terminations of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie Inc. 


  Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations. 


  "Through the tau and alpha-synuclein collaborations, we believe we have made considerable progress against targets for neurodegenerative diseases," the company said. 


  Voyager doesn't anticipate any changes to its cash runway guidance. 


  Write to Josh Beckerman at josh.beckerman@wsj.com